ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Clinical Infectious Diseases
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1576045
This article is part of the Research TopicDevelopment and Application of New Diagnostic Methods in Clinical Diagnosis of Virus-Related DiseasesView all 9 articles
Rapid detection of Golgi protein 73 by MAGLUMI chemiluminescent immunoassay and the clinical value to liver fibrosis/cirrhosis patients with chronic liver disease.
Provisionally accepted
Lu Wang1,2Wen Dai3Jie Rao4Yichen Wang4Kun Liu4Xing Li4
Hua Wang1,2Jiahuan Ye1,2
Xin Zheng1,2*
Zhonggang Fang4*- 1Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430022, P.R. China., Wuhan, China
- 2Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan 430022, P.R. China., Wuhan, China
- 3Department of Clinical Laboratory, Institute of Translational Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China., Wuhan, China
- 4Research & Development Department, Shenzhen New Industries Biomedical Engineering Co., Ltd., Shenzhen, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To investigate the diagnostic value of MAGLUMI chemiluminescent immunoassay (CLIA) for detecting Golgi protein 73 (GP73) in patients with chronic liver disease. Methods: A total of 212 patients with chronic liver disease were selected as the research subjects. METAVIR pathological staging was performed according to LSM values, and GP73 levels were detected by CLIA. Spearman analysis was used to analyze the correlation between GP73, LSM and METAVIR staging. The diagnostic efficacy of GP73 was analyzed using the ROC curve based on METAVIR staging. Results: The enrolled patients included 37 patients in F0/F1, 80 patients in F2, 61 patients in F3, and 34 patients in F4. There were significant differences in GP73 levels in each stage (p<0.001 for all stages). Spearman correlation analysis showed that GP73 levels were positively correlated with LSM and METAVIR stages. The AUC of GP73 in diagnosing significant liver fibrosis (F≥2), advanced liver fibrosis (F≥3), and cirrhosis (F=4) were 0.78 (95% CI: 0.72~0.84, p<0.0001), 0.83 (95% CI: 0.75~0.89, p<0.0001), 0.90 (95% CI: 0.80~0.96, p<0.0001), respectively. Conclusion: GP73 detected by CLIA was positively correlated with liver fibrosis stage and LSM, and had important clinical value in diagnosis of liver fibrosis and cirrhosis in patients with chronic liver disease.
Keywords: GP73, liver fibrosis, Immunoassay, performance evaluation, diagnosis
Received: 13 Feb 2025; Accepted: 17 Sep 2025.
Copyright: © 2025 Wang, Dai, Rao, Wang, Liu, Li, Wang, Ye, Zheng and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xin Zheng, xin11@hotmail.com
Zhonggang Fang, zhonggang_fang@snibe.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.